Abstract: The thioredoxin system plays a role in a variety of physiological functions, including cell growth, differentiation, apoptosis, tumorigenesis, and immunity. We previously confirmed that butaselen (BS), a novel thioredoxin reductase inhibitor, can inhibit the growth of various human cancer cell lines, yet the underlying mechanism remains elusive. In this study, we investigated the anti-tumor effect of BS in vivo through regulating the immune system of KM mice. We found that BS inhibits tumor proliferation by promoting the activation of splenic lymphocytes in mice. BS can elevate the percentage of CD₄⁻CD₈⁺ T lymphocytes and the secretion of downstream cytokines in mice via down-regulating the expression of programmed death-ligand 1 (PD-L1) on the tumor cells’ surface in vivo. Further study in HepG2 and BEL-7402 cells showed that decrease of PD-L1 level after BS treatment was achieved by inhibiting signal transducer and activator of transcription 3 (STAT3) phosphorylation. Taken together, our results suggest that BS has a role in promoting the immune response by reducing PD-L1 expression via the STAT3 pathway, and subsequently suppresses tumorigenesis.

新型硫氧还蛋白还原酶抑制剂丁烷硒啉通过下调PD-L1的表达来抑制肿瘤的发生

[1]Ahmad SM, Borch TH, Hansen M, et al., 2016. PD-L1-specific T cells. Cancer Immunol Immunother, 65(7):797-804.

[2]Chen J, Jiang CC, Jin L, et al., 2016. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol, 27(3):409-416.

[3]Fang W, Zhang J, Hong S, et al., 2014. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy. Oncotarget, 5(23):12189-12202.

[4]Fernandes AP, Capitanio A, Selenius M, et al., 2009. Expression profiles of thioredoxin family proteins in human lung cancer tissue: correlation with proliferation and differentiation. Histopathology, 55(3):313-320.

[5]Godoy-Ramirez K, Franck K, Gaines H, 2000. A novel method for the simultaneous assessment of natural killer cell conjugate formation and cytotoxicity at the single-cell level by multi-parameter flow cytometry. J Immunol Methods, 239(1-2):35-44.

[6]Grzywnowicz M, Karczmarczyk A, Skorka K, et al., 2015. Expression of programmed death 1 ligand in different compartments of chronic lymphocytic leukemia. Acta Haematol, 134(4):255-262.

[7]Hassan SS, Akram M, King EC, et al., 2015. PD-1, PD-L1 and PD-L2 gene expression on T-cells and natural killer cells declines in conjunction with a reduction in PD-1 protein during the intensive phase of tuberculosis treatment. PLoS ONE, 10(9):e0137646.

[8]He J, Li D, Xiong K, et al., 2012. Inhibition of thioredoxin reductase by a novel series of bis-1,2-benzisoselenazol-3 (2H)-ones: organoselenium compounds for cancer therapy. Bioorg Med Chem, 20(12):3816-3827.

[9]Kaimul Ahsan M, Nakamura H, Tanito M, et al., 2005. Thioredoxin-1 suppresses lung injury and apoptosis induced by diesel exhaust particles (DEP) by scavenging reactive oxygen species and by inhibiting DEP-induced downregulation of Akt. Free Radic Biol Med, 39(12):1549-1559.

[10]Lee J, Zhuang Y, Wei X, et al., 2009. Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis. J Mol Cell Cardiol, 46(2):169-176.

[11]Li Y, Li F, Jiang F, et al., 2016. A mini-review for cancer immunotherapy: molecular understanding of PD-1/PD-L1 pathway & translational blockade of immune checkpoints. Int J Mol Sci, 17(7):1151.

[12]Lu J, Holmgren A, 2014. The thioredoxin antioxidant system. Free Radic Biol Med, 66:75-87.

[13]Mahmood DF, Abderrazak A, El Hadri K, et al., 2013. The thioredoxin system as a therapeutic target in human health and disease. Antioxid Redox Signal, 19(11):1266-1303.

[14]Meng X, Huang Z, Teng F, et al., 2015. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev, 41(10):868-876.

[15]Meuillet EJ, Mahadevan D, Berggren M, et al., 2004. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN’s lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN’s tumor suppressor activity. Arch Biochem Biophys, 429(2):123-133.

[16]Mohler JL, Morris TL, Ford OH 3rd, et al., 2002. Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer. Prostate, 51(4):247-255.

[17]Nakamura H, Bai J, Nishinaka Y, et al., 2000. Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev, 24(1):53-60.

[18]Nomi T, Sho M, Akahori T, et al., 2007. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res, 13(7):2151-2157.

[19]O'Sullivan KE, Breen EP, Gallagher HC, et al., 2016. Understanding STAT3 signaling in cardiac ischemia. Basic Res Cardiol, 111(3):27.

[20]Siegel RL, Miller KD, Jemal A, 2017. Cancer statistics, 2017. CA Cancer J Clin, 67(1):7-30.

[21]Torre LA, Bray F, Siegel RL, et al., 2015. Global cancer statistics, 2012. CA Cancer J Clin, 65(2):87-108.

[22]Uçeyler N, Göbel K, Meuth SG, et al., 2010. Deficiency of the negative immune regulator B7-H1 enhances inflammation and neuropathic pain after chronic constriction injury of mouse sciatic nerve. Exp Neurol, 222(1):153-160.

[23]Vichai V, Kirtikara K, 2006. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc, 1(3):1112-1116.